Casdin Capital, LLC — 13F Holdings & Portfolio
CIK 1534261 · latest 13F-HR filed 2026-08-14
Casdin Capital, LLC manages $2.00B in 13F-reported U.S. long-equity assets across 43 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are RVMD (24.16%), RLAY (15.02%), WGS (12.74%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 3; 32 existing positions rose in reported value and 4 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 77.4%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
SUITE 2600
NEW YORK, NY 10019
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CANZONERI, LAWRENCE, JUDE Control | CHIEF FINANCIAL OFFICER since May 2019 | Less than 5% | Individual |
| CASDIN, ELI, D Control | MANAGING MEMBER since Aug 2011 | 75% or more | Individual |
| CRUPI, ANGELO Control | CHIEF COMPLIANCE OFFICER since Mar 2021 | Less than 5% | Individual |
| FISK, ALEXANDRIA Control | CHIEF OPERATING OFFICER since Jan 2020 | Less than 5% | Individual |
| GIORDANO, STEVEN, MICHAEL Control | GENERAL COUNSEL since Mar 2022 | Less than 5% | Individual |
Ownership & leadership changes · 9 filings with changes since Nov 20, 2013
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- No longer listedO'BRIEN, KEVIN, EUGENE · CHIEF LEGAL OFFICER · Less than 5% · control person · listed since Mar 2018
- AddedGIORDANO, STEVEN, MICHAEL · GENERAL COUNSEL · Less than 5% · control person
- AddedCRUPI, ANGELO · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedO'BRIEN, KEVIN, EUGENE · title CHIEF COMPLIANCE OFFICER → CHIEF LEGAL OFFICER
- No longer listedAPEADU, EVANS · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jul 2016
- AddedCANZONERI, LAWRENCE, JUDE · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- AddedFISK, ALEXANDRIA · CHIEF OPERATING OFFICER · Less than 5% · control person
- AddedO'BRIEN, KEVIN, EUGENE · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ChangedAPEADU, EVANS · title CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER → CHIEF FINANCIAL OFFICER
- ChangedCASDIN, ELI, D · title MANAGER → MANAGING MEMBER
- ChangedAPEADU, EVANS · title CHIEF FINANCIAL OFFICER → CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
- No longer listedEHRHART, MATTHEW, EVAN · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Mar 2014
- AddedAPEADU, EVANS · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ChangedEHRHART, MATTHEW, EVAN · title DIRECTOR OF FINANCE → CHIEF FINANCIAL OFFICER
- No longer listedSHIM, BRIAN, KISUNG · CHIEF COMPLIANCE OFFICER · Less than 5% · control person · listed since Aug 2011
- AddedEHRHART, MATTHEW, EVAN · DIRECTOR OF FINANCE · Less than 5% · control person
- ListedCASDIN, ELI, D · MANAGER · 75% or more · control person
- ListedSHIM, BRIAN, KISUNG · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- REVOLUTION MEDICINES INC$232.0M +92.6%
- RELAY THERAPEUTICS INC$156.6M +109.1%
- GENEDX HOLDINGS CORP$61.4M +31.8%
- ILLUMINA INC$27.9M +42.6%
- PERSONALIS INC$24.0M +235.3%
Top Trims
- STANDARD BIOTOOLS INC-$8.6M -10.5%
- 10X GENOMICS INC-$8.0M -16.6%
- ALNYLAM PHARMACEUTICALS INC-$2.2M -9.0%
- BRIDGEBIO ONCOLOGY THERAPEUT-$375.5K -14.9%
New Positions
- PARABILIS MEDICINES INC$17.7M
- SIONNA THERAPEUTICS INC$17.6M
- SAREPTA THERAPEUTICS INC$8.4M
- UNIQURE NV$6.9M
- EDITAS MEDICINE INC$1.4M
Casdin Capital, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | REVOLUTION MEDICINES INC | RVMD | 76155X100 | $482.7M | 24.16% | 2,577,333 | SH |
| 2 | RELAY THERAPEUTICS INC | RLAY | 75943R102 | $300.0M | 15.02% | 16,035,240 | SH |
| 3 | GENEDX HOLDINGS CORP | WGS | 81663L200 | $254.5M | 12.74% | 3,707,164 | SH |
| 4 | BIOLIFE SOLUTIONS INC | BLFS | 09062W204 | $131.5M | 6.58% | 4,655,000 | SH |
| 5 | ILLUMINA INC | ILMN | 452327109 | $93.2M | 4.66% | 530,000 | SH |
| 6 | STANDARD BIOTOOLS INC | LAB | 34385P108 | $73.0M | 3.66% | 88,783,856 | SH |
| 7 | STRUCTURE THERAPEUTICS INC | GPCR | 86366E106 | $63.1M | 3.16% | 1,175,000 | SH |
| 8 | DENALI THERAPEUTICS INC | DNLI | 24823R105 | $52.6M | 2.63% | 2,045,000 | SH |
| 9 | NEUROGENE INC | NGNE | 64135M105 | $48.6M | 2.43% | 1,545,361 | SH |
| 10 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $46.3M | 2.32% | 1,350,000 | SH |
| 11 | 10X GENOMICS INC | TXG | 88025U109 | $40.3M | 2.02% | 1,050,000 | SH |
| 12 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $36.6M | 1.83% | 665,000 | SH |
| 13 | PERSONALIS INC | PSNL | 71535D106 | $34.2M | 1.71% | 2,550,000 | SH |
| 14 | GRAIL INC | GRAL | 384747101 | $32.8M | 1.64% | 480,000 | SH |
| 15 | GUARDANT HEALTH INC | GH | 40131M109 | $27.8M | 1.39% | 185,000 | SH |
| 16 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $25.2M | 1.26% | 843,857 | SH |
| 17 | HIMS & HERS HEALTH INC | HIMS | 433000106 | $24.3M | 1.21% | 700,000 | SH |
| 18 | ALNYLAM PHARMACEUTICALS INC | ALNY | 02043Q107 | $22.6M | 1.13% | 75,000 | SH |
| 19 | TAYSHA GENE THERAPIES INC | TSHA | 877619106 | $22.1M | 1.11% | 3,250,000 | SH |
| 20 | AGOMAB THERAPEUTICS NV | AGMB | 00860C102 | $20.1M | 1.01% | 1,550,000 | SH |
| 21 | SEPTERNA INC | SEPN | 81734D104 | $18.5M | 0.93% | 553,268 | SH |
| 22 | PARABILIS MEDICINES INC | PBLS | 698955101 | $17.7M | 0.88% | 645,690 | SH |
| 23 | SIONNA THERAPEUTICS INC | SION | 829401108 | $17.6M | 0.88% | 400,000 | SH |
| 24 | VERACYTE INC | VCYT | 92337F107 | $16.2M | 0.81% | 276,308 | SH |
| 25 | ADLAI NORTYE LTD | ANL | 00704R109 | $14.4M | 0.72% | 1,250,000 | SH |
| 26 | PRIME MEDICINE INC | PRME | 74168J101 | $11.7M | 0.58% | 3,167,175 | SH |
| 27 | ABSCI CORPORATION | ABSI | 00091E109 | $11.3M | 0.56% | 973,260 | SH |
| 28 | QUEST DIAGNOSTICS INC | DGX | 74834L100 | $10.6M | 0.53% | 50,000 | SH |
| 29 | SAREPTA THERAPEUTICS INC | SRPT | 803607100 | $8.4M | 0.42% | 470,000 | SH |
| 30 | UNIQURE NV | QURE | N90064101 | $6.9M | 0.35% | 150,000 | SH |
| 31 | INTELLIA THERAPEUTICS INC | NTLA | 45826J105 | $6.0M | 0.30% | 355,000 | SH |
| 32 | MODERNA INC | MRNA | 60770K107 | $5.3M | 0.26% | 75,000 | SH |
| 33 | DISC MEDICINE INC | IRON | 254604101 | $4.8M | 0.24% | 65,000 | SH |
| 34 | MONTE ROSA THERAPEUTICS INC | GLUE | 61225M102 | $4.5M | 0.23% | 186,014 | SH |
| 35 | CENTURY THERAPEUTICS INC | IPSC | 15673T100 | $3.0M | 0.15% | 1,228,190 | SH |
| 36 | CONTINEUM THERAPEUTICS INC | CTNM | 21217B100 | $2.4M | 0.12% | 148,333 | SH |
| 37 | BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 107924102 | $2.2M | 0.11% | 282,312 | SH |
| 38 | EDITAS MEDICINE INC | EDIT | 28106W103 | $1.4M | 0.07% | 445,000 | SH |
| 39 | PACIFIC BIOSCIENCES CALIF IN | PACB | 69404D108 | $1.2M | 0.06% | 723,767 | SH |
| 40 | KARDIGAN INC | KARD | 485925101 | $1.2M | 0.06% | 50,000 | SH |
| 41 | RECURSION PHARMACEUTICALS IN | RXRX | 75629V104 | $606.7K | 0.03% | 165,323 | SH |
| 42 | GINKGO BIOWORKS HOLDINGS INC | DNA | 37611X209 | $361.6K | 0.02% | 36,493 | SH |
| 43 | TENAYA THERAPEUTICS INC | TNYA | 87990A106 | $267.5K | 0.01% | 361,969 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $2.00B | 43 | 0000919574-26-005491 |
| 2026-03-31 | 2026-05-15 | $1.32B | 40 | 0000919574-26-003451 |
| 2025-12-31 | 2026-02-17 | $1.61B | 38 | 0000919574-26-001181 |
| 2025-09-30 | 2025-11-14 | $1.20B | 32 | 0000919574-25-007006 |
SUITE 2600
NEW YORK, NY 10019